Publication | Open Access

Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen

Vancomycin-containing RegimenAntibioticsHealth SciencesHealthcare-associated InfectionVancomycin-intermediate Staphylococcus AureusAntimicrobial ChemotherapyInfection ControlMedicineClinical MicrobiologyAntimicrobial ResistanceDrug Resistance